Lung cancer : new understandings and therapies / Anne C. Chiang, Roy S. Herbst, editors.
Chiang, Anne C., editor.; Herbst, Roy, editor.
2021
RC280.L8
Available Online

Linked e-resources

Linked Resource Online Access
Concurrent users Unlimited
Authorized users Authorized users
Document Delivery Supplied Can lend chapters, not whole ebooks

Details

Title Lung cancer : new understandings and therapies / Anne C. Chiang, Roy S. Herbst, editors.
ISBN 9783030740283 (electronic bk.)
3030740285 (electronic bk.)
9783030740276
3030740277
DOI https://doi.org/10.1007/978-3-030-74028-3
Published Cham, Switzerland : Springer, 2021.
Language English
Description 1 online resource (vi, 264 pages) : illustrations (some color)
Other Standard Identifiers 10.1007/978-3-030-74028-3 doi
Call Number RC280.L8
Dewey Decimal Classification 616.99/424
Summary Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
Note Includes index.
Access Note Access limited to authorized users.
Source of Description Online resource; title from PDF title page (SpringerLink, viewed October 5, 2021).
Added Author Chiang, Anne C., editor.
Herbst, Roy, editor.
Series Current cancer research, 2199-2592
Available in Other Form Print version: 9783030740283
Print version: 9783030740276
Linked Resources Online Access
Record Appears in Online Resources > Ebooks
All Resources
Tumor Microenvironment: Immune Effector and Suppressor Imbalance
Biomarkers: is tumor mutational burden the new prognostic grail?
Liquid biopsies: new technology and evidence
Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance
What can we learn from acquired resistance?
Management of Brain Metastases
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
Therapeutic Advances in Small Cell Lung Cancer Management
Small Cell Lung Cancer: Biology Advances
Immunotherapy and Radiotherapy: New Strategies
Ultimate Precision: Targeting Cancer but not Normal Self-Replication
Index.

Browse Subjects

Show more subjects...

Statistics

from
to
Export